A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas.

被引：0
|
作者：
Abu Zaid, Mohammad Issam
Radovich, Milan
Althouse, Sandra K.
Liu, Hai
Spittler, Aaron John
Solzak, Jeffrey Peter
Hancock, Bradley Allen
Loehrer, Patrick J.
机构：
[1] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20580
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
    Kojima, Takashi
    Kato, Ken
    Hara, Hiroki
    Takahashi, Shunji
    Muro, Kei
    Nishina, Tomohiro
    Wakabayashi, Masashi
    Nomura, Shogo
    Sato, Akihiro
    Ohtsu, Atsushi
    Doi, Toshihiko
    ESOPHAGUS, 2022, 19 (04) : 702 - 710
  • [22] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA: AN IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM STUDY
    Wen, Patrick
    Yung, Alfred
    Mellinghoff, Ingo
    Lamborn, Kathleen
    Ramkissoon, Shakti
    Cloughesy, Timothy
    Rinne, Mikael
    Omuro, Antonio
    DeAngelis, Lisa
    Gilbert, Mark
    Chi, Andrew
    Batchelor, Tracy
    Colman, Howard
    Chang, Susan
    Nayak, Lakshmi
    Massacesi, Cristian
    DiTomaso, Emmanuelle
    Prados, Michael
    Reardon, David
    Ligon, Keith
    NEURO-ONCOLOGY, 2013, 15 : 134 - 134
  • [23] A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma, Cynthia X.
    Luo, Jingqin
    Naughton, Michael
    Ademuyiwa, Foluso
    Suresh, Rama
    Griffith, Malachi
    Griffith, Obi L.
    Skidmore, Zachary L.
    Spies, Nicholas C.
    Ramu, Avinash
    Trani, Lee
    Pluard, Timothy
    Nagaraj, Gayathri
    Thomas, Shana
    Guo, Zhanfang
    Hoog, Jeremy
    Han, Jing
    Mardis, Elaine
    Lockhart, Craig
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1583 - 1591
  • [24] A phase I dose-escalation study of buparlisib (BKM120), an oral pan-PI3K inhibitor, in Chinese patients with advanced solid tumors
    Zhang, L.
    Xu, B.
    Hazell, K.
    Gaur, A.
    Xu, J.
    Trandafir, L.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S186
  • [25] Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC)
    Chi, K.
    Castellano, D.
    De Bono, J.
    Gravis, G.
    Dirix, L.
    Machiels, J. P.
    Mita, A.
    Mellado Gonzalez, B.
    Massard, C.
    Trandafir, L.
    Dey, D.
    Csonka, D.
    Chakravartty, A.
    Fizazi, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S493 - S493
  • [26] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [27] Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
    Massard, Christophe
    Chi, Kim Nguyen
    Castellano, Daniel
    de Bono, Johann
    Gravis, Gwenaelle
    Dirix, Luc
    Machiels, Jean-Pascal
    Mita, Alain
    Gonzalez, Begona Mellado
    Turri, Sabine
    Maier, Joan
    Csonka, Denes
    Chakravartty, Arunava
    Fizazi, Karim
    EUROPEAN JOURNAL OF CANCER, 2017, 76 : 36 - 44
  • [28] Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics
    Azaro, A.
    Rodon, J.
    Vansteenkiste, J. F.
    Ando, Y.
    Doi, T.
    Mills, D.
    Sarr, C.
    Di Tomaso, E.
    Massacesi, C.
    Naumann, R. W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S186 - S186
  • [29] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [30] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM
    Wen, Patrick Y.
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Mellinghoff, Ingo K.
    Ramkissoon, Shakti
    Alexander, Brian
    Rinne, Mikael
    Colman, Howard
    Omuro, Antonio M.
    DeAngelis, Lisa M.
    Gilbert, Mark R.
    DeGroot, John
    Cloughesy, Timothy F.
    Lee, Eudocia Q.
    Nayak, Lakshmi
    Chi, Andrew S.
    Batchelor, Tracy
    Chang, Susan M.
    Prados, Michael D.
    Reardon, David A.
    Ligon, Keith L.
    NEURO-ONCOLOGY, 2014, 16
12345